An interventional study of GLP-1 and placebo in Heart Failure, Congestive, sponsored by Aarhus University Hospital Skejby. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-12-27.
Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Treatment
The purpose of this study is to determine whether 48 hours of glucagon-like-peptide-1 (GLP-1) infusion can improve heart function and alter substrate metabolism in non-diabetic patients with heart failure.
Heart failure is a major complication in patients with ischemic heart disease. It has been shown that many of these patients have areas of viable myocardium that are not effectively contributing to heart function.
Further, chronic congestive heart failure is associated with some degree of insulin resistance in both skeletal and cardiac muscle.
GLP-1 is a naturally occurring peptide hormone that acts as an incretin and has been intensively studied by many groups in association with type II diabetes and it has clearly shown its glucose lowering potential with very little risk of hypoglycemia in several trials.
Recently GLP-1 has been shown to improve cardiac function in dogs with pace-induced cardiomyopathy, and in an open-labeled study it did improve cardiac function in patients with acute myocardial infarctions.
Comparison: 48 hours of treatment with intravenous GLP-1 compared to placebo. Effect on global and regional left ventricular function, exercise capacity, insulin sensitivity and substrate metabolism.
5,703 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 20 is below the median of 72 across 3,737 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Aarhus University Hospital Skejby is the lead sponsor of 59 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: GLP-1
Drug: placebo
iv. by weight (1.0 pmol/kg/min )
same rate of infusion as GLP-1
Effect on global left ventricular function
Time frame: at baseline and after 48 hours of intervention
Effect on regional left ventricular function
Time frame: at baseline and after 48 hours of intervention
Effect on exercise capacity
Time frame: at baseline and after 48 hours of intervention
Effect on 6 minute walk test
Time frame: at baseline and after 48 hours of intervention
Effect on insulin sensitivity
Time frame: after 48 hours of intervention
Effect on substrate metabolism at whole-body level and in the fore-arm
Time frame: after 48 hours of intervention
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aarhus University Hospital Skejby